Cabaletta Bio, Inc. is a clinical-stage biotechnology company that uses chimeric autoantibody receptors (CAAR) technology to develop engineered T-cell therapies for patients suffering from B cell-mediated autoimmune diseases. Their proprietary CAAR T cells specifically bind and eliminate B cells that cause disease, such as autoantibodies and pathogenic B cells. They have a lead product candidate, DSG3-CAART, in Phase I clinical trials targeting autoimmune blistering skin disease and Hemophilia A with Factor VIII alloantibodies, as well as several other product candidates in different stages of development.